Yang Xiang Selected Research

Dactinomycin (Actinomycin)

1/2022	Efficacies of FAEV and EMA/CO regimens as primary treatment for gestational trophoblastic neoplasia.
12/2021	Results with Floxuridine, Actinomycin D, Etoposide, and Vincristine in Gestational Trophoblastic Neoplasias with International Federation of Gynecology and Obstetrics Scores ≥5.
5/2018	Pulse actinomycin D as first-line treatment of low-risk post-molar non-choriocarcinoma gestational trophoblastic neoplasia.
10/2016	Primary treatment of stage IV gestational trophoblastic neoplasia with floxuridine, dactinomycin, etoposide and vincristine (FAEV): A report based on our 10-year clinical experiences.
8/2014	[Expression of C1QBP gene and its correlation with drug resistance in human resistance choriocarcinoma cell line].
6/2014	Combination chemotherapy regimen with floxuridine, dactinomycin, etoposide, and vincristine as primary treatment for gestational trophoblastic neoplasia.
1/2014	[Clinical study on 39 cases with caesarean scar pregnancy with sonographic mass].
10/2007	Efficacy of the FAEV regimen in the treatment of high-risk, drug-resistant gestational trophoblastic tumor.
2/2006	[Efficacy of FAEV regimen in treatment of high-risk drug-resistant gestational trophoblastic tumor].
6/2004	EMA/EP chemotherapy for chemorefractory gestational trophoblastic tumor.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yang Xiang Research Topics

Disease

83	Neoplasms (Cancer) 01/2022 - 08/2002
35	Choriocarcinoma 11/2020 - 05/2003
29	Neoplasm Metastasis (Metastasis) 01/2022 - 08/2002
26	Inflammation (Inflammations) 05/2022 - 02/2006
25	Asthma (Bronchial Asthma) 01/2022 - 01/2008
23	Gestational Trophoblastic Disease (Trophoblastic Neoplasms, Gestational) 01/2022 - 09/2005
20	Uterine Cervical Neoplasms (Cancer of the Cervix) 06/2022 - 08/2003
15	Infections 01/2021 - 04/2007
13	Alzheimer Disease (Alzheimer's Disease) 01/2023 - 01/2015
12	Wounds and Injuries (Trauma) 01/2022 - 07/2006
10	Ischemic Stroke 03/2022 - 04/2015
9	Hydatidiform Mole (Molar Pregnancy) 01/2022 - 09/2005
8	Coronary Artery Disease (Coronary Atherosclerosis) 01/2022 - 04/2011
8	Trophoblastic Neoplasms (Trophoblastic Tumor) 01/2019 - 08/2003
7	Neuroinflammatory Diseases 01/2023 - 02/2015
7	Atherosclerosis 01/2022 - 01/2009
7	Carcinoma (Carcinomatosis) 01/2022 - 12/2004
7	Brain Neoplasms (Brain Tumor) 01/2022 - 12/2003
7	Breast Neoplasms (Breast Cancer) 01/2020 - 08/2009
7	Rheumatoid Arthritis 09/2018 - 05/2004
6	Hypoxia (Hypoxemia) 01/2023 - 06/2007
6	Hypertension (High Blood Pressure) 12/2022 - 02/2011
6	Endometrial Neoplasms (Endometrial Cancer) 01/2022 - 08/2003
6	Carcinogenesis 01/2019 - 05/2003
5	Stomach Neoplasms (Stomach Cancer) 01/2022 - 09/2011
5	Chronic Obstructive Pulmonary Disease (COPD) 11/2021 - 01/2014
5	Fibrosis (Cirrhosis) 01/2021 - 12/2008
5	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 05/2017
5	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 10/2007
5	Autoimmune Diseases (Autoimmune Disease) 02/2020 - 03/2011
5	Respiratory Hypersensitivity 01/2018 - 07/2007
5	Osteoarthritis 12/2015 - 05/2004
5	Lewis Lung Carcinoma 08/2011 - 08/2002
4	Obesity 12/2022 - 06/2007
4	Coronary Disease (Coronary Heart Disease) 12/2022 - 02/2011
4	Lymphatic Metastasis 08/2022 - 01/2015
4	Hemorrhage 01/2022 - 07/2009
4	Atherosclerotic Plaque (Atheroma) 01/2022 - 01/2019
4	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 01/2016
4	Respiratory Syncytial Virus Infections 12/2021 - 01/2008
4	Disease Progression 11/2021 - 05/2005
4	Teratoma (Teratoid Tumor) 10/2021 - 01/2012
4	Congenital Abnormalities (Deformity) 09/2021 - 07/2007
4	Ovarian Epithelial Carcinoma 01/2021 - 08/2003
4	Lung Neoplasms (Lung Cancer) 01/2021 - 10/2008
4	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 01/2020 - 01/2012
4	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2016 - 05/2004
4	Uterine Hemorrhage (Uterine Bleeding) 01/2014 - 12/2004
4	Leukemia 04/2013 - 08/2008

Drug/Important Bio-Agent (IBA)

40	Proteins (Proteins, Gene)FDA Link 01/2023 - 08/2002
32	Biomarkers (Surrogate Marker)IBA 01/2022 - 08/2008
25	Messenger RNA (mRNA)IBA 06/2021 - 06/2002
17	Biological ProductsIBA 01/2022 - 05/2003
17	Pharmaceutical PreparationsIBA 01/2021 - 05/2003
14	MicroRNAs (MicroRNA)IBA 04/2021 - 10/2008
13	IntegrinsIBA 09/2022 - 08/2011
12	Methotrexate (Mexate)FDA LinkGeneric 01/2022 - 06/2004
12	Floxuridine (FUdR)FDA LinkGeneric 12/2021 - 08/2003
11	CytokinesIBA 06/2021 - 09/2004
10	Dactinomycin (Actinomycin)FDA LinkGeneric 01/2022 - 06/2004
9	Etoposide (VP 16)FDA LinkGeneric 01/2022 - 06/2004
9	Chorionic Gonadotropin (Human Chorionic Gonadotropin)FDA LinkGeneric 10/2021 - 12/2003
8	AutoantibodiesIBA 03/2022 - 05/2004
7	DNA (Deoxyribonucleic Acid)IBA 05/2022 - 01/2010
7	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2022 - 05/2003
7	SmokeIBA 01/2021 - 03/2013
6	Amyloid beta-PeptidesIBA 01/2023 - 02/2015
6	Vincristine (Oncovin)FDA LinkGeneric 01/2022 - 02/2006
6	LigandsIBA 01/2022 - 02/2011
6	Cisplatin (Platino)FDA LinkGeneric 03/2014 - 06/2004
5	Glucose (Dextrose)FDA LinkGeneric 12/2022 - 01/2009
5	Circular RNAIBA 01/2022 - 01/2019
5	RNA (Ribonucleic Acid)IBA 04/2021 - 01/2015
5	AutoantigensIBA 08/2020 - 05/2004
5	Peptides (Polypeptides)IBA 01/2014 - 06/2007
4	OzoneIBA 01/2022 - 01/2007
4	alpha Catenin (alpha E-Catenin)IBA 01/2022 - 02/2008
4	AmidesIBA 12/2021 - 10/2019
4	Protons (Proton)IBA 12/2021 - 10/2019
4	ProteomeIBA 10/2021 - 07/2004
4	salicylhydroxamic acid (SHAM)IBA 01/2021 - 03/2013
4	Small Interfering RNA (siRNA)IBA 01/2021 - 08/2010
4	Long Noncoding RNAIBA 01/2021 - 01/2015
4	AerosolsIBA 01/2021 - 01/2020
4	PlatinumIBA 01/2021 - 10/2017
4	EnzymesIBA 01/2020 - 01/2014
4	AntigensIBA 11/2019 - 08/2010
4	NeuropeptidesIBA 01/2019 - 02/2006
4	Human beta Subunit Chorionic GonadotropinIBA 01/2018 - 01/2007
4	bombesin receptor subtype 3IBA 01/2018 - 07/2006
4	Ficusin (Psoralen)IBA 04/2013 - 08/2008

Therapy/Procedure

64	Drug Therapy (Chemotherapy) 01/2022 - 08/2003
29	Therapeutics 01/2023 - 12/2003
11	Hysterectomy 06/2022 - 01/2002
8	Lymph Node Excision (Lymph Node Dissection) 08/2022 - 12/2012
6	Neoadjuvant Therapy 03/2014 - 12/2008
5	Immunotherapy 01/2021 - 09/2019
5	Curettage 01/2020 - 12/2004
5	Cesarean Section (Caesarean Section) 06/2017 - 10/2003
4	Radiotherapy 10/2021 - 10/2018